As it’s estimated that the marketing of pharmaceutical products accounts for up to $25 billion of spending each year, there is a lot at stake for healthcare professionals everywhere. Understandably, a substantial amount of interest has arisen in the methodology used and the tactics employed by pharmaceutical companies as they deploy their sales organisations to contact and influence professionals. Some people feel that this industry requires more regulation and some factors have tried to influence the U.S. Congress to look more deeply into the business. With these dynamics in the background, the pharmaceutical company must take a highly focused and professional approach to the very way that it acts and how it reaches the people responsible for buying products and generating revenues enabling it to survive in the first place.
Certain countries around the World have been quick to introduce legislation and restrictions governing how pharmaceutical companies may interact with professionals. For example in Australia, codes of conduct have been established, with ethical marketing standards implemented and all member organisations must comply with the clearly laid out requirements or face legal action.
Pharmaceutical sales executives spend a large proportion of their time “detailing,” which refers to the act of visiting professionals and explaining the concept of the product, the reach, suggested markets, dosage, availability, side effects and other general industry news. Their communication skills must be absolutely excellent and sales executives must be able to systematically break down barriers that may have been built up over years of suspicion. Having said that, a sales executives is pivotal in bringing some vital information to the professional and supplementing the level of education. Much attention must be paid to these marketing methods by the pharmaceutical company.
Who knows whether restrictions or regulations may be brought into effect someday soon, thereby putting additional emphasis on an organisation’s effective marketing requirements? A company should engage pharmaceutical consulting firms due to the fact that they have direct experience and can as such help to train and educate the sales force so that they do not stumble at a vital time, make mistakes or negatively interact with professionals and spoil any potential gains.
Disclosure may be called for in future, detailing hospitality provided or suggested, levels of assistance given or gifts related and a clear indication of the style and type of education imparted. Not only will it be necessary for the sales executive to be highly educated in the product itself, fully understanding of restrictions and implications, but the executive must also be fully able to market to their highest ability.
Generally, pharmaceutical consultants will focus a great deal of their available time on striving to balance training between methods and product awareness. Staff will be trained in the essential elements of time management, and in addition to the dissemination of traditional marketing skills, any up-to-date or new legal requirements will be the subject of focus. Company chiefs should outsource these methods to pharma consulting, enabling them to focus on other areas. With ineffective marketing, reputations can be compromised and there can be other implications, including problems with regulations and authorities; consultants must steer the organisation carefully.
Alan Gillies is the CEO of L2L Consulting, a cutting-edge pharma consultancy firm which specialises in optimising productivity and performance within international companies by applying tailored organisational strategies.